Scalper1 News
Intercept Pharmaceuticals (ICPT) said Thursday that it had stopped a phase-two clinical trial of a liver-disease drug because it had already met its endpoint, sending the stock soaring 245% to near 270 in morning trading in the stock market today. The phase-two trial had been testing a substance called obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis, in which the liver can be damaged by excessive fat accumulated around it. Scalper1 News
Scalper1 News